Literature DB >> 23539465

Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.

David Linton1, Alasdair M Barr, William G Honer, Ric M Procyshyn.   

Abstract

This systematic review examines treatment guidelines, efficacy/effectiveness, and tolerability regarding the use of antipsychotics concurrently with psychostimulants in treating aggression and hyperactivity in children and adolescents. Articles examining the concurrent use of antipsychotics and psychostimulants to treat comorbid attention deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs) were identified and their results were summarized and critically analyzed. Antipsychotic and stimulant combination therapy is recommended by some guidelines, but only as a third-line treatment following stimulant monotherapy and stimulants combined with behavioral interventions to treat aggression in patients with ADHD. Some studies suggest efficacy/effectiveness for an antipsychotic and stimulant combination in the treatment of aggression and hyperactivity in children and adolescents. However, the data do not clearly demonstrate superiority compared to antipsychotic or psychostimulant monotherapy. Most studies were performed over short time periods, several lacked blinding, few studies used any placebo control, and no comparisons were made with behavioral interventions. There are concerns about the tolerability of combination therapy, but data do not suggest significantly worse adverse effects for combination compared to either antipsychotic or stimulant monotherapy. Conversely, and contrary to speculation, use of a stimulant does not significantly reduce metabolic effects of antipsychotics. Combination treatment with antipsychotics and psychostimulants is used frequently, and increasingly more often. Few studies have directly examined this combination for the treatment of ADHD and DBDs. Further studies are necessary to confirm the efficacy and tolerability of the concurrent use of antipsychotics and psychostimulants in children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23539465     DOI: 10.1007/s11920-013-0355-6

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  46 in total

Review 1.  Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management.

Authors:  Nancy Scotto Rosato; Christoph U Correll; Elizabeth Pappadopulos; Alanna Chait; Stephen Crystal; Peter S Jensen
Journal:  Pediatrics       Date:  2012-05-28       Impact factor: 7.124

Review 2.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

3.  Excessive antipsychotic dosing in a Canadian outpatient population.

Authors:  Alasdair M Barr; William J Panenka; William G Honer; Sejal Khara; Ric M Procyshyn
Journal:  Psychiatr Serv       Date:  2011-06       Impact factor: 3.084

4.  Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity.

Authors:  A Weizman; R Weitz; G A Szekely; S Tyano; R H Belmaker
Journal:  J Am Acad Child Psychiatry       Date:  1984-05

Review 5.  Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Authors:  Jik H Loy; Sally N Merry; Sarah E Hetrick; Karolina Stasiak
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

6.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

7.  Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.

Authors:  William G Kronenberger; Ann L Giauque; Deborah E Lafata; Bradley N Bohnstedt; Laura E Maxey; David W Dunn
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-06       Impact factor: 2.576

8.  The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Authors:  Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin
Journal:  Health Serv Res       Date:  2012-09-04       Impact factor: 3.402

9.  Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics.

Authors:  Nick C Patel; Monica Hariparsad; Mary Matias-Akthar; Michael T Sorter; Drew H Barzman; John A Morrison; Kevin E Stanford; Stephen M Strakowski; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-06       Impact factor: 2.576

10.  A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.

Authors:  Linmarie Sikich; Robert M Hamer; Robert A Bashford; Brian B Sheitman; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

View more
  16 in total

1.  Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study.

Authors:  L J S Schweren; C A Hartman; M P Zwiers; D J Heslenfeld; D van der Meer; B Franke; J Oosterlaan; J K Buitelaar; P J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-11-14       Impact factor: 4.785

2.  Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more.

Authors:  Ahmed Naguy
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

3.  Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.

Authors:  Dean Elbe; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  J Psychiatry Neurosci       Date:  2014-05       Impact factor: 6.186

4.  Behavioral Weight Loss Treatment in Antipsychotic Treated Youth.

Authors:  Ginger E Nicol; Rachel P Kolko; Monica Mills; Thrudur Gunnarsdottir; Michael D Yingling; Julia A Schweiger; Eric J Lenze; John W Newcomer; Denise Wilfley
Journal:  Scand J Child Adolesc Psychiatr Psychol       Date:  2016-05

5.  Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment.

Authors:  Ginger E Nicol; Lisa de Las Fuentes; Amy E Riek; Carlos Bernal-Mizrachi; Eric J Lenze; J Phillip Miller; Julia A Schweiger; Michael D Yingling; Vincent J Huang; David J Dixon; Charles H Hennekens; John W Newcomer
Journal:  J Clin Endocrinol Metab       Date:  2015-07-17       Impact factor: 5.958

6.  Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.

Authors:  Dominik Stämpfli; Stefan Weiler; Andrea M Burden
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-07-03       Impact factor: 4.785

Review 7.  DSM-5: disruptive mood dysregulation disorder.

Authors:  Uma Rao
Journal:  Asian J Psychiatr       Date:  2014-03-15

8.  Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.

Authors:  Carsten Schröder; Michael Dörks; Bianca Kollhorst; Tilo Blenk; Ralf W Dittmann; Edeltraut Garbe; Oliver Riedel
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-09-13       Impact factor: 4.785

9.  Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.

Authors:  Drigissa Ilies; Anne-Sophie Huet; Eric Lacourse; Geneviève Roy; Emmanuel Stip; Leila Ben Amor
Journal:  Can J Psychiatry       Date:  2017-07-04       Impact factor: 4.356

10.  Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment.

Authors:  Gail A Edelsohn; Kemal Eren; Meghna Parthasarathy; Neal D Ryan; Amy Herschell
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.